# BioIQ

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioiq

- Industry: Medical Devices & Equipment
- Headquarters: Atlanta, US
- Website: www.bioiq.com
- Total disclosed funding: $29M
- Latest round: Series G (Mar 8, 2018)
- Investors on record: 3

## About

BioIQ Inc. is a provider of consumer-centric health testing and immunization services, enhancing access to vital healthcare diagnostics and treatment solutions across the United States.Founded in 2005, BioIQ Inc. is headquartered in Atlanta, US, and specializes in innovative health testing services. The company was acquired by PrivaPath Diagnostics Limited in November 2021, expanding its reach and capabilities. Justin Bellante founded BioIQ, and under CEO Markus Ollikainen, it has successfully navigated the healthcare landscape. The company has raised a total of USD 14.00 mn through various funding rounds, with its latest funding being Series H, and currently holds a valuation of USD 75.855 mn.BioIQ, now a LetsGetChecked company, specializes in consumer-centric health testing and immunization services designed to enhance access to healthcare diagnostics and treatment. The company's core offerings include a comprehensive suite of over 100 diagnostic tests that range from at-home testing for various health conditions to telehealth consultations and pharmacy capabilities. These services cater to a diverse clientele, including Fortune 500 companies, government agencies, and over 50 health plans, aiming to address consumer needs for convenient and reliable health insights. BioIQ's products are widely available across the United States, tapping into the growing demand for at-home healthcare solutions that empower individuals to manage their health proactively. Through their platform, the company seeks to modernize healthcare by providing accessible, on-demand treatment options for chronic conditions and enhancing overall healthcare outcomes.Revenue generation for BioIQ is achieved through a mix of direct-to-consumer sales and B2B partnerships, leveraging its innovative healthcare solutions. Clients, which include health plans and corporate partners, can access BioIQ's diagnostic testing services, which are structured around subscription models or contractual agreements tailored to their specific healthcare needs. The company facilitates transactions by offering a flexible pricing structure for its health tests and services, ensuring accessibility for clients while delivering high-quality healthcare solutions. BioIQ's flagship offerings focus on integrating lab testing with telehealth support, creating a seamless experience for end-users. This strategic combination allows BioIQ to maintain a steady revenue stream while continuously expanding its client base and service capabilities within the healthcare market.Looking ahead, BioIQ aims to enhance its product lineup with new health testing solutions, although specific release dates have not been disclosed. Geographic expansion is also a priority, with plans to extend services into additional regions within the US in the coming years. The acquisition by PrivaPath Diagnostics Limited will enable the integration of BioIQ’s services with a broader portfolio, ultimately aiming to enhance consumer and partner access to healthcare diagnostics and treatment options.

## Funding rounds

- Series G, Mar 8, 2018, $27M — Arboretum Ventures, HealthQuest Capital
- Series B, Feb 20, 2008, $2.5M — Persistence Partners

## Investors

- Persistence Partners (https://capitalatlas.ai/funds/persistence-partners) — Series B
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series G
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series G